The University of Chicago
Chicago, Illinois, 60637, United States
NCT Number: NCT04120805
The purpose of this study is to evaluate the necessity of using hemostatic agents as a tool when performing robotic partial nephrectomy in the treatment of kidney cancer. This project asks whether patients who undergo robotic partial nephrectomy without the surgeon using hemostatic agents during the procedure will have the same, fewer, or more complications than when patients undergo this same surgery with the surgeon using hemostatic agents during the procedure.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Not applicable
Chicago, Illinois, 60637, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients undergoing robotic-assisted laparoscopic partial nephrectomy with the use of hemostatic agents by a surgeon
Patients undergoing robotic-assisted laparoscopic partial nephrectomy without the use of hemostatic agents by a surgeon
Time frame: up to 6 months
The change in hemoglobin will be measured as the difference between the hemoglobin obtained postoperatively and the hemoglobin obtained preoperatively.
Time frame: up to 6 months
Major complications are blood loss requiring transfusion of packed red blood cells, reoperation and endovascular ablation
Time frame: up to 6 months
Safety monitoring parameters including stroke, death, cardiac arrest, myocardial infarction and urine leak
Time frame: up to 6 months
Operating room parameters including number of sutures used during renorrhaphy and capsular closure, duration of renorrhaphy and patients in group 2 with no hemostatic agents who required HA at the surgeons discretion
Time frame: up to 6 months
Total length of all inpatient hospital stay over 30 days measured in days
University of Chicago
Other
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02974738
Adenocarcinoma, Advanced Solid Tumors
View Trial DetailsNCT01217931
Adenocarcinoma, Carcinoma
Houston, Texas, United States
View Trial DetailsNCT05520099
Adenocarcinoma, Bladder Cancer
Little Rock, Arkansas, United States
View Trial DetailsNCT05820087
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Los Angeles, California, United States
View Trial Details